Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

As Asia grappled with the impact of the Iran war, a major pharmaceutical milestone quietly made the headlines. On March 20, the patent for semaglutide, the active ingredient in Novo Nordisk’s Ozempic ...

The most significant addition to the Java language since Sun Microsystems rewrote the collections API for Java 5 is the introduction of Java records. Java records address two significant pain points ...

NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The rapid entry of semaglutide generics is beginning to weigh on the growth of Eli Lilly’s tirzepatide brand Mounjaro, even as the broader market expands, data from pharma market intelligence and data ...

Java developers absolutely must learn Maven. Maven is the most popular and pervasive build tool in the Java world. Even if you don't use Maven directly, alternatives such as Gradle, Jenkins or Ivy ...

MUMBAI, (IANS) – Pharma major Lupin Limited has said that it has launched Mirabegron extended-release tablets, 25 mg, in the US market, after having received approval from the Food and Drug ...

LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...

Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...

In a significant development for diabetes treatment, Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) for its generic version of dapagliflozin tablets, ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...